Please login to the form below

Not currently logged in
Email:
Password:

wet AMD

This page shows the latest wet AMD news and features for those working in and with pharma, biotech and healthcare.

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

The new drug could halve the number of injections into the eye that are needed by wet AMD patients from 13 with Lucentis to six or eight, according to the duo, ... CEDAR and SEQUOIA both compared the two drugs on their ability to prevent the progressive

Latest news

More from news
Approximately 18 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • Pharma deals during May 2014 Pharma deals during May 2014

    Top of the list was Ophthotech's commercialisation and co-development agreement with Novartis for Fovista, an anti-PDGF agent, in phase 3 for wet age-related macular degeneration (AMD). ... Coincidentally two weeks earlier, there was another deal for a

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    22. Tracon Pharmaceuticals/ Santen Pharmaceutical Co. Licence. Tracon's anti‐ endoglin antibodies, including TRC105 for wet AMD (p2).

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    effectiveness over Novartis' Lucentis (ranibizumab) in the treatment of wet age-related macular degeneration (AMD).

  • Revolution or evolution: is it the end of SMR and ASMR in France? Revolution or evolution: is it the end of SMR and ASMR in France?

    An example of this is Lucentis in wet age-related macular degeneration (AMD), where the expectation is that there should be pricing parity between Lucentis and Avastin, an oncology drug used

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics